EUREKA Institute International Certificate Program May 5th - May 11th 2013 Siracusa, Italy
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
EUREKA Institute International Certificate Program May 5th - May 11th 2013 Siracusa, Italy
EUREKA
Institute
International Certificate
Program
May 5th - May 11th 2013
Siracusa, Italy
The Three Pillars EUREKA’S MISSION
The Eureka educational The Institute’s mission is to develop a community of translational medicine
initiative is based on: professionals equipped to catalyze the application of discoveries for the
benefit of human health. We do this by educating and building a community.
- an attitude of teamwork
- critical thinking skills Overall Educational Objectives
- knowledge of translational Participants in the Certificate Program will:
medicine
1. A nalyze the business, scientific and regulatory aspects of Translational
Medicine (TM)
2. Explore the challenges professionals encounter in TM
3. Develop critical thinking skills to approach the challenges in Translational
Medicine
4. Develop communication skills for presenting various topics to a broad
spectrum of people
5. A nalyze effective manuscript preparation and begin to apply the concepts
to their own work
Educational Strategies
We use a number of educational strategies to achieve the overall course
objectives and the goals of each individual activity. Key among these is
creating an open and safe environment through which participants can
navigate, and in which participants may interact.
2
Support thank Erica Roks for her contributions. In addition,
we thank our Artist-in-Residence Kate Breakey for
We thank the kind support of the Center for contributing her time and passion in cultivating the
Translational Molecular Medicine, Danone 2013 Translational Creativity program. We also
Centre for Specialised Nutrition, the acknowledge Gianfranco Grompone for his enthusiam
Dutch Arthritis Association, EULAR, in designing the creative collaborations session.
EUTRAIN, the Institute of Medical Science, Lastly, we thank Francesco Italia, Vittorio di Natale,
Nature Medicine, the Sanford-Burnham and their colleagues at the Borgia del Casale for their
Medical Research Institute, SingHealth, TI extraordinary efforts, gastronomic artistry, and for
Pharma, University College London, and the the beautiful space in which the course is held.
University Medical Center Utrecht.
We deeply appreciate the Faculty for the 2013 Inter-
national Certificate Program. They are generously
donating their time and expertise to participate in
the course. We are also grateful for the time and
effort contributed by our board, which includes Salvo
Albani, David Hafler, Janet Hafler, Juan Carlos Lopez,
Jan Vos van Marken, Berent Prakken, Norm Rosen-
blum, and Vicki Seyfert-Margolis. Our sincere grati-
tude goes to Jessica Colomb, who provides energy,
vision, and cohesion to this Program. We want to
recognize the dedicate effort and commitment of the
PeopleRise team, Marco Abbate and Bob Chinello. We
2009 Participants and Faculty
Edited and compiled by The Eureka Institute for purposes, for resale, for creating new collective
Translational Medicine works, or for commercial proprietary purposes,
is strictly prohibited.
A publication of the Eureka Institute for
Translational Medicine. Prepared in the partial Eureka Institute for Translational Medicine
fulfillment of the requirements for the certificate of
completion. Continuing Medical Education credits Requests for reprints or reproduction to:
are not being offered for this course, however the Eureka Institute for Translational Medicine
materials are in compliance with the requirements c/o Jessica Colomb
of the Accreditation Council for Continuing Medical 629 4th Street,
Education. Course materials and handouts include Encinitas, CA USA 92024
edited and compiled works of multiple authors. +1 (619) 820-2272
info@eurekainstitute.org
Reproduction of this document or any part thereof,
or the additional materials offered throughout the
course is governed by US copyright law (US Code,
Title 17). Copying material contained in this
document or other course materials for general © 2013 Eureka Institute for Translational Medicine
distribution, for advertising or promotional All Rights Reserved
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
3
Course Venue About the Program
Most of the lectures, case studies and mentoring You will find in the following pages:
sessions will be held at the Borgia del Casale, - a brief introduction to Eureka and translational
located in the Piazza Duomo in the heart of medicine ‣
Ortigia. - basic logistical information
- course materials organized by day
Address: At Borgia del Casale, - faculty, artist and participant bios
Via Picherali 10, Stairs B, Interno
4 (of f the piazza Duomo) This is a living document that will grow and change
Siracusa. with you as you move through the course. Because we
focus on active participation rather than passive
Rooms dedicated for the conference: processes, the program will be tailored to your needs
Salotto dei Viaggiatori and expectations, both predefined and those that
Salotto delle Arti arise in situ. The program materials are organized
Alcova chronologically. For each session, you will find an
Stanza degli specchi abstract as well as its principal learning objectives.
Lunches and the opening and closing dinner will Each day will start at 8:30a with coffee and brief
be held in the Dehor, and the Dammusi. social period, which will segue into the first session
of the day (at 9a). The course is balanced between
In the event that you need to contact didactic sessions, interactive discussion, and practi-
the venue: cal application. Please make opportunities to
Telephone: +39 0931 22509 synthesize the discussions and explore, in a personal
Mobile: +39 335 256201 and +39 339 548804 context, how the topics covered can be applied to
your own work. Course evaluations will be collected
at the end of each day.
ABOUT TRANSLATIONAL MEDICINE
Key Data
Today, the term “translational medicine” is a buzzword in biomedical sciences
Coffee Service and with a rapidly increasing number of meetings about it; courses on it; and
Informal Discussion: institutes dedicated to it. A simple Pubmed search on “translational medicine”
8:30a generates over 29,000 papers, while a google search yields nearly 9,000,000 hits.
Because of its popularity and its increased use, the meaning of the term
Start Time: 9:00a translational medicine has become progressively ambiguous and is often used
synonymously with clinical testing.
Wine and Cheese
Events: Monday, In our opinion, translational medicine encompasses the continuum of activities
Wednesday, and that extend from the conception of an idea all the way into Phase II/III clinical
Friday testing and, ultimately, the development of a tangible product. This itinerary
includes multiple and diverse components requiring very different skills and
Dinners: Sunday and competencies ranging from molecular medicine to pharmacology; from animal
Saturday Night testing to clinical trial design; from intellectual property to venture capital.
Translational medicine is therefore the framework needed to ensure the evolution
of novel technologies into tangible benefits for patients.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
4
Eureka Faculty Roster - May 2013
Marco Abbate, B.Sc., Carol Gregorio, Ph.D., Frank Miedema, Ph.D., Vicki Seyfert-Margolis,
M.Sc, Cpsychol, Peopler- Professor of Cell Biology Dean and Vice Chairman Ph.D., Chief Scientific
ise, Partner and Anatomy, and of the Board and profes- and Strategy Officer,
Molecular and Cellular sor of Immunology, Precision Health Hold-
Salvatore Albani, M.D., Biology; Member, BIO5 University Medical ings; CEO and Founder,
Ph.D., Professor and Institute; Director, Centre Utrecht, the My Own Med
Director, Translational Molecular Cardiovascu- Netherlands
Medicine, Infectious and lar Research Program;
Inflammatory Diseases, Co-Director, Sarver Martin Offringa, M.D.,
Sanford-Burnham Heart Center, The Uni- Ph.D., Senior Scientist
Medical Research versity of Arizona and Program Head, Child
Institute Health Evaluative
David Hafler, M.D., Chief Sciences CHES, Research
Roberto Chinello, M.B.A., and Chair of Neurology, Institute, The Hospital
B.S. Economics, Peopler- Yale New Haven Hospital for Sick Children, Uni-
ise, Partner and Yale School of versity of Toronto
Medicine
Hans-Georg Eichler, Berent Prakken, M.D.,
M.D., M.Sc., Senior Janet Hafler, Ed.D., Ph.D., Professor of
Medical Officer, Euro- Professor of Pediatrics, Pediatric Immunology at
pean Medicines Agency Assistant Dean for the University Medical
Educational Scholarship, Centre Utrecht, the
Dirk Elewaut, M.D., Yale School of Medicine Netherlands;
Ph.D., Professor of
Rheumatology and Paul Krieg, Ph.D., Profes- Maria Grazia Roncarolo,
Immunology; Head, sor of Cell Biology and M.D., Ph.D., Scientific Eureka Artist-
Laboratory for Molecular Anatomy and Molecular Director, San Raffaele in-Residence
Immunology and Inflam- and Cellular Biology, The Scientific Institute;
mation; Division of University of Arizona Professor of Pediatrics, Kate Breakey, M.F.A.,
Rheumatology, a EULAR School of Medicine and Artist, Photographer
and FOCIS Center of Juan Carlos Lopez, Ph.D., Surgery, San Raffaele
Excellence; Ghent Editor-in-Chief, Nature Vita-Salute University;
University Hospital Medicine Chief of Clinic, Pediatric
Immunology and Hema- Eureka Observers
Wainwright Fishburn, Jan Vos van Marken, tology and Clinical
J.D., Partner, Cooley M.B.A, Director, Research Unit (CRU-P) Enny Kiesworo, B.Sc,
Godward Kronish LLP UNOVATE (a University San Raffaele Hospital MHA, M.Sc, Director,
Medical Centre Utrecht and San Raffaele Scien- Office of Research,
Patricia Furlong, R.N., holding company for tific Institute, Milan, SingHealth
B.S.N., M.S., Founding service companies) Italy.
President and Chief Ingrid Lether, M.Sc,
Executive Officer, Parent Andrew Marshall, Ph.D., Norm Rosenblum, M.D., Head of Research,
Project Muscular Dystro- Editor-in-Chief, Nature Professor of Paediatrics, Reumafonds
phy Biotechnology Canada Research Chair
in Developmental Ne- Howard Mount,
Johan Garssen, M.D., Patrick Maxwell, FMed- phrology, and Associate Ph.D., Graduate
Ph.D., Professor, Immu- Sci, Regius Professor of Dean, Physician Scientist Coordinator, Institute
nopharmacology, the Physic & Head of the Training, University of for Medical Science;
University of Utrecht; School of Clinical Medi- Toronto Assistant Professor,
and Director, Immunol- cine, University of Division of
ogy, Danone Research Cambridge Neurology, University
Centre for Specialized of Toronto
Nutrition, Wageningen,
the Netherlands
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
5
SUNDAY, MAY 5th
Coffee Objectives
Time: 8:30 - 9:00 1. Discuss trajectory of a pediatric rare disease
diagnosis
Introductions 2. Identify opportunities and time points for inter-
Facilitator: Janet P. Hafler, Ed.D. vention, support, engagement
Time: 9:00 - 10:00 3. Discuss the ecosystem of rare diseases and
o
pportunities
Mapping Translational Medicine
Presenters: Salvatore Albani, M.D., Ph.D., and Berent for partnership between healthcare professionals,
Prakken, M.D., Ph.D. researchers, parents /family members and the
Time: 10:05 - 10:50 biopharmaceutical industry
Abstract
In this session, the objectives of the course and Group Lunch, 12:20 - 13:20
concepts of translational medicine will be introduced
and defined.
Conceptual Basis for Clinical Experimentation
Objectives in the Era of Precision Medicine
1. Define the field of translational medicine Presenter: Salvatore Albani, M.D., Ph.D.
2. Analyze the components involved Time: 13:25 - 14:25
3. Discuss the challenges of translational medicine
Abstract
This conversation will address the general principles
Break, 10:55 - 11:10 inspiring the "druggability" of compound, technology
or process. In other words, what are the key factors
influencing the evolution of a scientific discovery or
Finding a Therapeutic Dose of Hope concept through the translational gradient to answer
Presenter: Patricia Furlong, B.S., M.S.N. an unmet medical need. A lot of science is
Time: 11:15 - 12:15 outstanding, but not all of it is "druggable".
Abstract Objectives
Patients and family members, when faced with a 1. Highlight the principles guiding movement from
catastrophic diagnosis (rare or otherwise) feel iso- initial investigations into “advanced” studies
lated and alone. The dreams and plans for the life 2. Discuss designing and managing clinical trials,
they imagined are gone. Parents with sick children including data management and interpretation
feel as if they have failed parenthood, no longer able 3. Explore the intersection of interests between key
to ‘fix’ things or dry every tear. They have few choices stakeholders (e.g. patients, regulators and business)
and by default, become an advocate. They search the
internet, sign up for Google alerts, connect
on FB and Twitter. They join registries. They learn a Break, 14:30 - 14:45
new language and may travel long distances to find
physicians with expertise and interdisciplinary care.
They start foundations and form virtual biotech
companies. They become caregivers, caretakers,
pseudo scientists and doctors, investors and part-
ners. They educate family, extended family, school,
community and every physician they will ever meet.
They learn a new language, drive regulatory science
and healthcare policy. They navigate systems and
actively campaign for change. They are aggressive,
fearless and effective. They have one single goal –
TIME.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
6
SUNDAY, MAY 5th Day 1 Evaluations Collected
The Case Study Method Mentoring Session I
Presenter: Janet P. Hafler, Ed.D. Time: 16:50 - 17:35
Time: 14:50 - 15:20
Abstract and Goals
Abstract As part of the course, participants will present a
In this session, the large-group, case study method dilemma they are currently facing to a small group of
will be contextualized, and the variety of teaching peers. This group will be mentored by faculty.
methods used during the course will be presented. Fellow course participants will act as a consultation
group. The objective is to advance personal learning
Objectives while practicing and improving approaches to, and
1. Define the learning method organization of, problem solving. Reflections using
2. Practice critical thinking skills practical real-world problems will anchor the con-
cepts raised in the didactic portion of the program.
“Sisyphus”, A Case Study
Facilitator: Norman Rosenblum, M.D.
Written by: Salvatore Albani, M.D., Ph.D. and Jessica
Colomb, B.A. Social Program (Sunday)
Time: 15:25 - 16:25
Wine and Cheese, and Dinner
Abstract 20:00
“Sisyphus” is based on a real case about the develop-
ment of a novel immunotherapeutic strategy. It Please join us to celebrate the 5th Annual
focuses on compounds designed specifically for International Certificate Program in
humans. Sisyphus addresses typical problems in Translational Medicine. Appetizers precede the
proof-of-concept studies, development and regulation. dinner. Both will be served at the Borgia del
This case also prevents incongruities in animal Casale.
models of disease versus human application.
Objectives
1. Explore strategies for lead identification
2. Explore strategies for chemistry, manufacturing
and controls (CMC) studies (funding and conduct)
3. Explore strategies for safety data in untraditional
models
Translational Creativity Introduction
Artist / Facilitator: Kate Breakey
Time: 16:30 - 16:45
Abstract
I am a mixed media artist. I work with photography,
(light) and pigment (paint) and I translate ideas into
substance. I hope to inspire 29 translational medicine
participants to get involved in some translational
creativity with me. During this Eureka week, we will
collaborate to make an artwork as a team. The plan
is to integrate many small parts into a larger whole
that becomes more that the sum of those parts. We
will use produce from the local Sicilian market as our
raw materials and classical Italian still life painting
as our inspiration.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
7
MONDAY, MAY 6th
Pick Up Time, 8:30 sharp Social Program (Monday)
Team Building Day Wine and Cheese
Facilitators: Marco Abbate, B.Sc., M.Sc, Cpsychol, and 19:00 - 20:15
Bob Chinello, M.B.A., B.S.
Logistical Note: Participants will meet in the Piazza Special Presentation: Traveling as a Scientist
Archimedes at 8:30 am EXACTLY on Monday morn- Presenter: David Hafler, M.D., Ph.D.
ing. Busses will be waiting to pick you up and Time: 19:30 - 19:50
transport you to the beach where the team building
exercise is being held.
Time: 8:30 - 16:30
Abstract
The team building exercise will be led by Bob and
Marco, of Peoplerise and will be comprised of a series
of group activities to help the participants to make a
better use of their teams by understanding team
dynamics and the “social ingredients” of effective
interaction.
Objectives: Dig into some important issues related to
“being in a team”
1. When does a “loose affiliation of individuals”
become a team?
2. Group decision-making: relationship, negotiation,
conflict and feedback: join the party!
3. Team dynamics: communication, trust, diversity,
alignment, common objectives
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
8
TUESDAY, MAY 7th
Coffee mal growth factor receptor 2-positive breast cancer,
Time: 8:30 - 9:00 J Clin Oncol. 2009 Dec 1;27(34):5838-47. Epub 2009
Nov 2. Review. PMID: 19884552
Group Dynamics
Presenter: Janet P. Hafler, Ed.D. Objectives
Time: 9:00 - 9:30 Through this case, participants will grapple with the
development of a therapy intended for a targeted
Abstract sub-population, and explore the issues arising in the
In this session the team building exercise will be post-market phase. In addition, participants will
discussed. The participants will begin to identify discuss and determine research and business strate-
effective group member behaviors and one’s role on a gies necessary to "translate" a potential therapeutic,
team, in addition to developing a network of col- and co-develop its companion biomarker. Parallel
leagues. concepts of collaboration and team will also be
explored.
Objectives
1. Define what constitutes a team
2. Discuss principles of effective group interaction Break,10:40 - 10:55
3. Discuss networks and their influence on career and
science
Predictive Models in Pharmcovigilence and
The Magic Bullet, Unfolding Case Study Personalized Medicine
Written by: Vicki Seyfert-Margolis, Ph.D. Presenters: Hans-Georg Eichler, M.D., Vicki Seyfert-
Time: 9:35 - 10:35 Margolis, Ph.D.
Time: 11:00 - 12:00
Abstract
This case examines the full translational tightrope of Abstract
a targeted therapy, from lead identification to Phase Predictive markers, toxicology models, and tools to
II and III clinical trials. Participants will work in help shape intelligent drug design and diagnostic
depth with the case in a small group setting over development will be explored.
three separate sessions.
Objectives
Recommended reading will be provided: 1. I dentify state of art technologies for predicting
Slamon DJ et al. Use of chemotherapy plus a monoclo- toxicology and efficacy
nal antibody against HER2 for metastatic breast 2. D iscuss use of the above to optimize the develop-
cancer that overexpresses HER2. N Engl J Med. 2001 ment of new therapies
Mar 15;344(11):783-92. PMID: 11248153. Available at 3. Explore principles of intelligent design of drug
http://www.nejm.org/doi/full/10.1056/ development
NEJM200103153441101
Spector NL, Blackwell KL. Understanding the mecha- Group Lunch, 12:05 - 13:05
nisms behind trastuzumab therapy for human epider-
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
9
TUESDAY, MAY 7th cont.
Pre-Market Medical Product Development Abstract
Presenters: Vicki Seyfert-Margolis, Ph.D.; and Hans- The research is complete. The data have been col-
Georg Eichler, M.D. lected and analyzed. But this is no time to rest. The
Time: 13:10 - 14:10 paper has to be written. Publication in a peer-re-
viewed journal is almost an automatic requirement
Abstract for a researcher to be able to move a concept into
A background on the latest trends in pre-market more advanced stages of development. This session
product development including biomarkers, diagnos- will explore the publication process from an editor’s
tics, devices, drugs and biologics will be discussed perspective, and also how this ties into good research
with respect to the applied science of product devel- practices.
opment needed to move more innovative products to
the market for patients who need them. Various Objectives
aspects involved in the science needed to improve 1. Define the key elements to include in a paper
product development, from pre-clinical to clinical 2. Discuss the most common mistakes to avoid
trials will be described as well as the latest policies 3. Discuss how to create a publication strategy
under discussion in the United States and Europe.
Objectives Day 2 and 3 Evaluations Collected
1. Discuss the latest trends, gaps and opportunities in
the applied science of product development and
evaluation (regulatory science).
2. Describe the stakeholders, priorities and up to date In Session Break, 15:55
efforts ongoing in regulatory science.
3. Examine the various policy discussions surround-
ing pre-market product development from discov- “Speed Dating”, Session 1
ery to market launch, including funding, regula- Facilitators to be announced, sign up sheet will be
tory, reimbursement, and other considerations. distributed
Time: 16:05 - 17:15
Break, 14:15 - 14:30 Abstract and Objectives
“Speed dating” provides the opportunity for partici-
pants to have a series of one-on-one discussions with
Presentation Workshop Primer individual faculty for 10 minutes each. Topics are the
Presenter: Janet P. Hafler, Ed.D. participant’s choice. Please consult the faculty
Time: 14:35 - 14:50 biographies at the end of this program prior to
completing the signup sheet, which will be availabe
Abstract Sunday afternoon, and Tuesday through lunch.
The design of the presentation workshop will be
introduced. The workshop will focus on content, Translational Creativity, Gathering the Parts
form, audience assessment and delivery. Artist / Facilitator: Kate Breakey
Time: 15:55 - 18:00
The Mysteries of Communication
Presenters: Juan Carlos Lopez, Ph.D. and D. Hafler In parallel with the “Speed Dating” session, we will
M.D., Ph.D. begin to gather and put together the individual
Time: 14:55 - 15:55 components of the still life painting. We will pass
around a sign up sheet for your dedicated time slots.
Please be sure you have purchased your item by
Tuesday morning at the latest.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
10EFFECTIVE PRESENTING FORMAT
A. S
tart with a brief statement of the goal to be
addressed in your presentation and indicate who
you consider to be the target audience.
B. P resent for up to five minutes. Your colleagues will
participate as the audience and the presentation
will be videotaped.
C. 1) You, the presenter, will then view the videotape
on your own and, as it plays and for a short time
after, develop a list of strengths and suggestions
for personal improvement.
2) While the presenter views the tape, the "audi-
ence" of colleagues discusses the strengths of the
presentation and suggestions for improvement.
Suggestions should
- Deal with behavior, not with the person.
- Focus on strengths as much as possible.
D. The presenter and the audience reconvene, each
providing feedback on strengths and suggestions.
The purpose of this discussion is to:
- allow for self-reflection on the part of the pre-
senter and feedback in the context of suggestions
for future teaching.
- define and authenticate issues in teaching.
-p rovide an occasion for others to help if
appropriate.
You will present for up to 5 min.
(and be videotaped)
Review your video Group discusses and
on your own (5 min.) critiques the presentation
You return to group
comment on your review
receive feedback (5 min.)
references: Hewson, MG, Little ML. Giving feedback in medical educaiton: verifaction of recommended techniques. J Gen Intern
Med. 1988;13(2):111-116.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
11THE PRESENTATION WORKSHOP
Observation Guide
Process
1. How does the presentation begin?
- How does the presenter capture attention and
promote curiosity?
- How is the overview presented?
2. Is the information presented in a well organized
manner?
3. P resentation: Is the delivery paced to the audience’s
capacity to follow?
- Does the presenter avoid reading notes?
-D oes the presenter show any distracting
mannerisms?
- Did the presentation start and end on time?
4. How does the presenter promote active
participation? Does he/she
- use movement?
- make eye contact with the audience?
- use aids?
- ask questions that prompt reflection or response?
- use buzz groups, voting or brainstorming?
- problem solve?
5. How does the presentation conclude?
- Is there a review?
- Are there follow-up tasks?
- Is there an evaluation (the one-minute paper)?
6. How is learning assessed?
Content
1. Is the content accurate?
2. Does the presenter show a relationship between
theory and practice?
3. Is the level of the material appropriate to the
audience?
4. Was the presentation complete?
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
12THE PRESENTATION WORKSHOP
Feedback Tips
Definition:
The process of giving data back to the participant for
the purpose of bringing about change.
Feedback involves responding specifically to an event
or occurrence, whether that event be good or bad.
Positive and negative feedback should be
distinguished from complimenting and criticizing.
Evaluation is an assessment of a learner’s
achievement and/or performance.
1. Feedback should be undertaken with the observer
and participant working as allies with common
goals. Begin by discussing respective
expectations.
2. Feedback should be descriptive rather than
evaluative.
3. Feedback should deal with specific events, rather
than generalizations.
4. Feedback should be well-timed, and expected, in
close proximity to the event, but not when — the
recipient is postcall or angry about the issue; facts
are missing; or both sides of the situation have not
been explored.
5. Feedback should be based on first-hand data.
6. Feedback should be focused on behaviors that are
amenable to change.
7. Feedback should involve sharing of information,
rather than giving advice, leaving the receiver free
to decide for themselves in accordance with their
own goals and needs.
8. Feedback can be structured to include subjective
data, as long as it is clearly labeled as such.
9. Feedback should be checked to insure clear
communication by having the receiver try to
rephrase the feedback.
10. Feedback should be followed by attention to the
consequences of feedback.
Taking the Plunge
1. Be clear about the purpose of the feedback session.
2. G et the receiver’s perspective as to how things are
going.
3. The sandwich technique (i.e., good / bad / good)
isn’t always reliable.
4. Ask the recipient to offer solutions.
5. Develop solutions to the problem, and a plan to
improve the situation.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
13WEDNESDAY, MAY 8th
Coffee Objectives
Time: 8:30 - 9:00 1. Describe the science of post-market evaluation and
science.
Debriefing 2. P rovide participants with an overview of some of
Time: 9:00 - 9:25 the large scale efforts around post-market
evaluation
The Evolution of the Drug Development 3. Explore the science surrounding Patient-Centered
Paradigm Outcomes Research
Presenter: Andrew Marshall, Ph.D. 4. D iscuss some of the latest trends in interfaces to
Time: 9:30 - 10:30 the post-market product landscape, including
health information technologies.
Abstract
Drug development has undergone a profound trans-
formation over the past century, from a loosely (In Session Break)
regulated, chemistry-driven field to one of the most
highly regulated industries with an increasing
emphasis on biology and technological advances. The Magic Bullet, Unfolding Case Study
This talk will briefly summarize this transformation continued
to then focus on a discussion on the current state of Written by: Vicki Seyfert-Margolis, Ph.D.
the drug-discovery enterprise, examining some of the Time: 11:40 - 12:40
commonly held views about its workings.
Objectives Group Lunch,12:45 - 13:45
1. I ntroduce participants to the current state of the
drug-development enterprise
2. A nalyze and challenge common beliefs about the Modeling diseases and therapies in experi-
way drug development works in an interactive mental systems
discussion Presenters: Norman Rosenblum, M.D.
3. Critically think about how these views hamper or Time: 13:50 - 14:50
help the drug-development process
Abstract
Regulatory Science II: Science and Policy of Animal models are commonly used to model human
Medical Product Post-Market Landscape diseases. But how reliable are these models? How
Presenters: Hans-Georg Eichler, M.D., Vicki does the researcher decide? Participants will analyze
Seyfert-Margolis, Ph.D. dilemmas researchers can face while working with
Time: 10:35 - 11:35 animal models.
Abstract Objectives
The session will provide a background on the latest 1. Discuss when and why to use animal models
efforts to address post-market monitoring and 2. Examine how to use animal models
evaluation of products, including the science of 3. Explore the differences between animal models
patient monitoring, post-market safety and efficacy and human diseases
considerations, the impact of health information
technology and electronic medical records, impact of
health care systems and policies, such as reimburse- Break,14:55 - 15:10
ment in the United States and national health care
systems in Europe. Additionally, Comparative
Effectiveness or Patient-Centered Outcomes Research
efforts and impacts will be covered, as well as policy
discussions surrounding these areas.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
14WEDNESDAY, MAY 8th cont.
Sicilian Delicacies
Navigating Late-Stage
Clinical Development The title for the “Gastronomic Capital” of Italy is
Presenter: Hans-Georg Eichler, M.D. certainly a matter for debate. While some would
Time: 15:15 - 16:15 claim it to be in the Northern regions of the
country (specifically Bologna), the South is rich
Abstract with fresh delicacies. As an island, it makes
A well-executed translational medicine program will sense that fish would rank among these fine foods.
bring a novel therapy through proof-of-concept to Bluefin tuna is native of Sicilian waters and
beginning Phase 3 trials. Successful navigation of sought throughout the world, especially Japan.
late-stage development requires careful coordination Fishing techniques date back well over a
of teams with proficiency in multiple key scientific millennium, with some traceable to Arab rule,
disciplines as well as regulatory expertise. and others suspected to be vestiges from the
Carthaginian period. Tonnarotti (Italian for tuna
Objectives fisherman), might recommend a simple breaded
1. Discuss milestone regulatory interactions that take tuna steak, while others could tout the finer
place in late-stage development. qualities of “purpetti” (tuna croquettes), or
2. Identify various ways that biomarkers can aid “salsiccia di tonno” (tuna sausage), or even tuna
clinical development. stew. However, one cannot live on fish alone
3. Identify changes contributing to growing interest (arguably).
in orphan diseases on the part of biotechnology
companies and big Pharma. Arabic influences transcends savory dishes, and
inspires the sweet. Honey, almonds, and sesame
seeds are all linked with the Arabic era in Sicily.
Day 4 Evaluations Collected They are also the main ingredients for sweets in
Siracusa. The “giuggiulena” is a perfect example.
Giuggiulena is a hard candy made from exactly
Mentoring Session II those three ingredients. Pistachios, ricotta cheese
Facilitators to be determined and chocolate also grace many recipes. Consider
Time: 16:20 - 17:35 the “cassata siracusana” with ricotta cheese and
chocolate, or perhaps save your calories for
Abstract and Objectives authentic and irreproducible Sicilian cannoli.
See session 1 (Monday) for abstract and obectives Since we’ll be in Siracusa during the Santa Lucia
festival, one might try a “cuccìa”, made with
ricotta cheese and candied squash and fruit.
Granita (an icy concoction with almond milk) is
paradise on a hot summer day.
After all this eating, you might be thirsty. One
thing to try (aside from granita) is Nero d’Avola.
Social Program The origin of the varietal is unknown, and has
thus far only been found in Sicily. A sweeter
(Wednesday) palate will revel in the wine described by Homer
and Hesiod: Moscato di Siracusa, which is
rumored to be oldest wine in Italy.
Wine and Cheese Whatever your preference, Siracusa is sure to
19:00 - 20:00 have something unique and delectable for you.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
15THURSDAY, MAY 9th
Coffee Break,14:15 - 14:30
Time: 8:30 - 9:00
Debriefing Emerging Models in Translational Medicine
Time: 9:00 - 9:25 Presenters: Johan Garssen M.D., Ph.D.; Vicki Seyfert-
Margolis, Ph.D.
Presentation Workshop Time: 14:35 - 15:35
Time: 9:30 - 12:00
Abstract
Abstract Danone research for specialized nutrition runs
Participants will give a 5 minute presentation. Peers research programs in both Asia and Europe, as well
and faculty will critique the presentation, and the as the United States. This session will examine issues
presenter will self-evaluate. unique to multi-national and inter-institutional
research collaborations.
Objectives
1. Evaluate the best methods for delivering a message Objectives
2. Explore strengths and areas of improvement in 1. D
iscuss bridging different research cultures
your personal presentation style (lab-work, management, coordination) and local
3. Develop presentation / communication skills traditions
2. E xplore how to organize funding in different parts
of the world
Group Lunch,12:05 - 13:05 3. Examine the challenges of new industries/
initiatives
Science 3.0 The Magic Bullet, Unfolding Case Study
Presenter: Frank Miedema, Ph.D. continued
Time: 13:10 - 14:10 Written by: Vicki Seyfert-Margolis, Ph.D.
Time: 15:40 - 16:25
Abstract
When people think of a scientist, they often think of
someone who has his or her head in the clouds, Day 5 Evaluations Collected
motivated by an entirely untainted desire for the
pursuit of knowledge and truth. In this presentation
Frank Miedema will cast aside these beliefs about In Session Break,16:25 - 16:40
scientists as needlessly naïve, and instead suggest
that we rebuild our idea of the sciences, particularly
the life sciences, with today’s economic reality in Speed Dating II
mind. Facilitators to be determined
Time: 16:35 - 17:50
Objectives
1. Understand the impact of external forces on Abstract and Objectives
Science as it relates to translational Medicine “Speed dating II” provides another opportunity for
2. Develop awareness of the way science shapes both participants to have a series of one-on-one
economic and social progress in modern society discussions with individual faculty for 10 minutes
3. Realize how increasing pressure to solve real-world each. Topics are the participant’s choice. Please
problems has forced scientists out of the ivory consult the faculty biographies at the end of this
tower and into the corporate world. program prior to completing the signup sheet, which
will be availabe Sunday afternoon, and Tuesday
through lunch.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
16FRIDAY, MAY 10th
Siracusa
Coffee
Time: 8:30 - 9:00 Some 2,700 years ago, one of the first Greek
settlers dubbed this area “Sirako”. This was in
Debriefing reference to the surrounding salt marshes,
Time: 9:00 - 9:25 beautiful areas dense with sensitive and highly
specialized vegetation. Its strategic location and
Mentoring Session III saavy inhabitants helped make Siracusa one of
Facilitators to be determined the most powerful city-states in all of Magna
Time: 9:30 - 10:30 Grecia. Cicero called it “the most beautiful of
them all”. Ruling factions have changed over
Abstract and Objectives time, with the Romans, Byzantines, Arabs,
See session 1 (Monday) for abstract and obectives Normans and Swabians all fighting for supremacy
in the region. Sicily (and Siracusa) has survived
The role of technology transfer in academic each invasion, and absorbed some important
translational medicine influences evident today. For example, May is the
Presenter: Maria Grazia Roncarolo, M.D., Ph.D. opening month of the Greek Theatre, a premier
Time: 10:35 - 11:35 theatrical event in all of Italy. Architecture
further infuses the bones of the city, doric and
Abstract ionic, baroque and roccoco. And art (high and
Investigators developing technologies in an academic low, old and new) adorns the city-scape and
setting need to have the tools to evaluate the options enriches its museums.
that are available to them, when to utilize academic
resources, and when to seek other options. This Siracusa is not buried in its past, however. The
session will examine the TM itinerary in relation to city’s heartbeat is strong with the song of the
the respective roles of academia, IP, patents and dolce vita; “ragazzi” enjoy the night life sitting at
technology transfer. an open-air coffee-shops, or dancing in one of the
many clubs that are concentrated in the area
Objectives between Piazza Archimede, Piazza Duomo, the
1. Explore the pathway of IP development within an Aretusa Fountain and the Alfeo Promenade.
institution
2. Discuss the benefits and detriments of technology
transfer
3. Discuss the options, obligations, and strategies of
the investigator
Group Lunch,12:10 - 13:10
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
17FRIDAY, MAY 10th cont.
A Stroll in the Valley of Death: Strategies for Break,14:20 - 14:35
Developing a Start-up in the Current Climate
Presenters: Salvatore Albani, M.D., Ph.D; Wainwright
Fishburn, J.D.; Juan Carlos Lopez, Ph.D. From Mountains to Molehills: Transforming Basic
Time: 13:15 - 14:15 Research into Leads
Presenter: Paul Krieg, Ph.D.
Abstract Time: 14:40 - 15:40
The “Valley of Death” is a term typically used to
describe the vast expanse between an idea and its Abstract
delivery to patients and the market. The valley is Basic molecular research generates interesting data
cloaked by the fog of unawareness and swept by the and concepts. While conducting successful and
winds of uncertainty. Many dangers lurk in it. We insightful experimentation can be rewarding, it is
will discuss the various challenges which have to be only the gestational step of translational research. In
overcome, including but not limited to funding in the this session, participants will discuss how to evalu-
current climate. We will suggest strategies to maxi- ate basic research discoveries for leads and give
mize the chances of success. Our objective is to examples of successful basic science studies leading
disperse the fog and provide awareness of the to clinical insights.
process.
Objectives
Objectives 1. Identify what a lead is and its key elements
1. Identify the elements leading to the formation of a 2. I dentify strategies for evaluating basic molecular
company as a development vehicle for a transla- science for translational potential
tional idea 3. Discuss the next steps once a lead is identified
2. Describe the current funding process as well as
funding policies and their impact
3. Examine the challenges start-ups encounter in Day 6 Evaluations Collected
developing an idea into a product tangibly
benefitting patients
Social Program (Friday)
Wine and Cheese
19:00 - 20:00
Special Presentation: Creative Collaborations
Presenter: Gianfranco Grompone, Ph.D.
Time: 19:20 - 19:40
During Creative Collaborations we will explore
the links between art and translational medicine
through an unique musical experience of
collaborative creation. Together we will step into
uncertainty to create an original group
composition.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
18SATURDAY, MAY 11th
Coffee Abstract
Time: 8:30 - 9:00 This interactive seminar will explore the issue of
individual achievement and cooperation in the
Debriefing context of translational research. Methods to en-
Time: 9:00 - 9:25 hance cooperation will be explored. The limits of the
'cooperation model' will be highlighted and 'conflict-
Grant Writing Workshop resolution' theory will be harnessed to propose a
Facilitators: Carol Gregorio, Ph.D., Paul Krieg, Ph.D., method by which investigators can achieve a higher
and Norm Rosenblum, M.D. state of cooperation and greater achievement in
Time: 9:30 - 11:00 research.
Abstract Objectives
Participants will focus on elements of persuasive 1. H ighlight tensions between individual and team-
grant writing using samples of their own grant based achievement in research.
summary pages as a foundation. 2. Understand limits of the conventional model of
cooperation.
Objectives 3. Explore use of conflict-resolution theory to reach a
1. Explore effect structures (e.g. abstract flow) higher stage of cooperation and achievement in
2. Examine content for message clarity and delivery research.
3. Learn self-assessment strategies for written work
Small Piece, Big Pie Break,14:35 - 14:40
Presenters: Dirk Elewaut, M.D., Ph.D., Berent Prak-
ken, M.D., Ph.D.
Time: 11:05 - 12:20 “Sisyphus”, A Case Study
Facilitator: Norman Rosenblum, M.D.
Abstract Time: 14:40 - end of session
This interactive session will discuss the pitfalls of
collaborative research in translational medicine. Abstract
Various partners (academic institutions, industry, This case study is based on epitope-specific immuno-
regulatory authorities, etc) are implicated when therapy and focuses on compounds designed specifi-
pursuing research in this area. cally for humans. Sisyphus addresses typical prob-
lems in proof-of-concept, development and regulation.
Objectives This case also includes the incongruities in animal
1. Identify differences in approaching collaborative models of disease versus human application.
research with different organizations (academia
versus industry) Objectives
2. Discuss the issue of intellectual property and confi- 1. Explore strategies for lead identification
dentiality 2. E xplore strategies for chemistry, manufacturing
3. Identify strategies to tackle obstacles in collabora- and controls (CMC) studies (funding and conduct)
tive research 3. Explore strategies for safety data in untraditional
models
Group Lunch, 12:25 - 13:25
Final Course Evaluations, approximately
16:15 - 17:00
The “I” / “We” Dilemma, or Is Cooperation an
Ingredient to My Success
Facilitators: Norman Rosenblum, M.D., Berent Prak- Social Program (Saturday)
ken, M.D., Ph.D.
Time: 13:30 - 14:30 20:00 CLOSING DINNER: After a week of hard work,
creativity and fun, please join us for an amazing
dinner with enticing wines. Dinner will be serve
at the Borgia del Casale in the historical suite of
Regina Lucia.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
19EUREKA TRANSLATIONAL CREATIVITY
The birth of Translational Creativity Research Fellow at the Institute for Public and Urban
In 2011, the time was ripe for the Eureka Institute for Affairs at San Diego State University, and Artist-In-
Translational Medicine to add Art into their program: Residence at the Institute for Art and Olfaction in Los
Eureka Translational Creativity was born. Since May Angeles. His work has been screened, performed, and
2011, Eureka has created work space for artists exhibited throughout the United States, Canada,
during the Siracusan course to collaborate with and Austria, Italy, China, Croatia, and the Netherlands.
reflect on the field of Translational Science. Selected projects include: Sillage, Hammer Museum,
UCLA (2013); Adaptive Equipment, Lust Gallery,
The first invited artists were Brian Goeltzenleuchter Vienna, Austria (2011); c (pronounced /k/) Wellness
and Anna van Suchtelen. In 2011, they were in resi- Centre, Southern Alberta Art Gallery, Canada (2010);
dence in Sicily, which resulted in the film When to c Boutique, Museum of Contemporary Art, San Diego
Throw a Painting to a Drowning Man, released in (2010); Sponge X Sponge, Colorado State University
2012. (2007); Institutional Wellbeing, Centrum Beeldende
Kunst, The Netherlands (2006); Who’s not for sale,
Banff Centre, Canada (2006); Unpacking Iraq,
2011-2012: When to Throw a Painting to a International Festival of New Film/New Media Split,
Drowning Man Croatia (2004)
Anna van Suchtelen (New York 1961) studied
The project: Literature (MA) in Groningen, the Netherlands and
Visual Arts at University of California San Diego,
When to Throw a Painting to a Drowning Man is an USA. Over the years she professionally moved from
artist-made self help video that shows how creativity literary editor to visual artist. Text and narrative
can be useful to anyone. The video offers parables play a crucial role in her visual work, which includes
and exercises that evoke the structure of a self help installations, audio works and film. Her projects,
book. It celebrates the transcendent nature of creativ- often context-specific and interactive, explore the
ity, examining its potential as a skill and tool for senses, memory and time. Her work has been
problem solving, critical thinking, networking, and exhibited and screened in the Netherlands, the United
team building. States, Canada, Italy, India and Japan.
Selected projects include: Our Airs Conspire,
Artists Brian Goeltzenleuchter and Anna van installation with heat, sound and breathing (2013);
Suchtelen were invited by the Eureka Institute for Pelgrim Kootwijk, interactive walk (2012); I got life!,
Translational Medicine to participate in its installation with shower curtain and soundtrack
international workshop designed to train a new class (2011); Lindenduft, installation with memory
of translational researcher. The artists developed cupboards and film (2010); Soft Voices, installation
this video to highlight the false dilemma of with listening glasses and film (2009); Overtocht, film
considering art and science as binary opposites. (2009) and performance on a ferry (2008)
Focusing, instead, on the commonality of innovation,
the artists produced this video for an audience of
innovators who strive to come to terms with the
uncertainty that accompanies working
collaboratively and across disciplinary borders.
The artists:
Brian Goeltzenleuchter (b. 1976) is an artist based in
San Diego, USA. His work employs interdisciplinary
research in the creation of designed environments,
scripted and improvised performances, olfactory art,
photography, and video. His recent projects
investigate the use-value of cultural objects and
institutions. In 2001 Goeltzenleuchter received his
MFA from the University of California, San Diego.
From 2002 - 2008 he was Associate Professor of Art at
Central Washington University. He is currently a
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
20EUREKA TRANSLATIONAL CREATIVITY
For the 2013 program, photographer Kate
Breakey has been invited. She will be in
residence in May, for which she proposed the
work The Syracuse Still Life.
2013: The Syracuse Still Life
The project: The artist:
I am a mixed media artist. I work with photography Kate Breakey is internationally known for her
(light) and pigment (oil paint, pencils and pastels) and large-scale, richly hand-colored photographs
I translate ideas into substance. My work has been including her series of luminous portraits of birds,
heavily influenced by early Northern European flowers and animals. Since 1980 her work has
painting. I am hoping to inspire 29 translational appeared in more than 85 one-person exhibitions and
medicine participants to get involved in a in over 50 group exhibitions. Her work is held in
translational creativity project with me. During the many public institutions. A native of South Australia,
Eureka week, we will collaborate to make an artwork Kate moved to Austin, Texas in 1988. She completed a
as a team. We will use produce from the local Sicilian Master of Fine Art degree at the University of Texas
market as our raw materials and classical Italian still in 1991 where she also taught photography in the
life painting as our inspiration to construct a still life Department of Art and Art History until 1997. In
tableau. Each participant will be documented with 1999, she moved to Tucson, Arizona. Her 4th book, a
their contribution, in the style of Renaissance collection of photograms, entitled 'Las Sombras / The
portraiture. The objective is to integrate many small Shadows' was publish in 2012.
parts into a larger whole that becomes more that the
sum of those parts.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
21EUREKA Institute Faculty Disclosures & Faculty BIOGRAPHIES
Faculty DISCLOSURES
Nothing to disclose:
Salvatore Albani, M.D., Ph.D.
Hans-Georg Eichler, M.D., M.Sc.
Johan Garssen, M.D., Ph.D.
Carol Gregorio, Ph.D.
Jan Vos van Marken, M.B.A
Frank Miedema, Ph.D.
Martin Offringa, M.D., Ph.D.
Berent Prakken, M.D., Ph.D.
Norm Rosenblum, M.D.
Juan Carlos Lopez, Ph.D.
Patricia Furlong, R.N., B.S.N., M.S.
Janet Hafler, Ed.D.
Wainwright Fishburn, J.D.
Maria Grazia Roncarolo, M.D., Ph.D.
Disclosures
David Hafler, M.D. discloses an affiliation with
Allozyne Inc., Bayer Yakuhin, Ltd, Genzyme, Sanofi-
Aventis, US, Inc., McKinsey and Company, NKT
Therapeutics, Novartis Pharmaceuticals, Biogen, Teva
Neuroscience, Pfizer, Sage Therapeutics, and the
Cleveland Clinic Foundation as a consultant.
Paul Krieg, Ph.D. discloses an affiliation with
Angionics as a consultant and major stock holder.
Disclosure not available at time of printing:
Marco Abbate, B.Sc., M.Sc
Roberto Chinello, M.B.A., B.S.
Dirk Elewaut, M.D., Ph.D.
Andrew Marshall, Ph.D.
Patrick Maxwell, FMedSci
Vicki Seyfert-Margolis, Ph.D.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
23Faculty BIOGRAPHIES
Marco Abbate BSc, MSc,
Cpsychol
I am a Chartered Occupational Psychologist in the UK My model is based on the psychodrama. Psychodrama
and in Italy. My ten years’ experiences as a Chartered uses dramatic action to examine problems or issues
Occupational Psychologist in several fields and nearly raised by an individual. Through experiential
eight years in coaching and recruitment have allowed methods, sociometry, role theory, and group
me to acquire a well-rounded profile. I work with dynamics, psychodrama facilitates insight, personal
international SME (small and medium enterprises) on growth, and integration on cognitive, affective, and
projects related to organisational development, behavioural levels. It clarifies issues, increases
coaching, recruitment and training. numerous physical and emotional well being, and enhances
international projects in the UK, Italy, Germany, learning and develops new skills.
Spain and China have taught me and continue to
teach me that living and working together in an
organisation is an issue that scares both management
and their team, and is and will be a great challenge
for the organisations and those working within. Please find me in
Please find more about me: uk.linkedin.com/in/ marco.abbate@peoplerise.net
marcoabbate/
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
24Faculty BIOGRAPHIES
Salvatore Albani,
M.D., Ph.D.
My fundamental research interest is in Development of high throughput technology
understanding human immunity and contributing platforms is also part of my scientific career. These
the knowledge to therapeutic and diagnostic platforms aim to provide tools for knowledge-based
advancements. I have developed several innovative diagnostic and therapeutic decisions (various papers
approaches in the area of induction and maintenance and patents under review).
of immune tolerance in humans, being responsible for
the whole translational process from idea to the In addition, I have developed a technology for the
conclusion of a Phase II clinical trial in autoimmune identification and manipulation ex vivo of antigen-
inflammatory diseases, which have a large impact on specific T cells. This technology, named T cell
society and individuals. I have been responsible for capture, is based on entirely artificial antigen
conception and execution of each of the stages of this presenting cells. It has applications in
complex itinerary, which spans a wide and diverse immunotherapy of cancer and treatment of infections
gradient of technologies and challenges. in an immunocompromised host (Nature Medicine, JI.
Blood, A&R, Haematologica, various patents).
These include molecular immunology, lead Combined, these approaches span both ways across
identification and validation, intellectual property, the gradient of Translational Medicine, which is
CMC (Chemistry, Manufacturing and Controls), IND evidence of and underscores my dedication to this
(Investigational New Drug filings), trial design, data field.
management and analysis, interfacing with Venture
Capital and Pharma, leading complex groups in a In my role as an educator, it has been my privilege to
multi-center setting, etc. The technology platform has mentor many talented individuals, and to provide the
applications in diseases that could benefit from a right challenges and learning opportunities to help
restoration of immune tolerance. This translational them grow and advance. I seek to expand this even
research itinerary has been the original backbone of further by helping to create and nurture the next
my career, as witnessed by a rich publication trail generation of translational scientists. An important
(among others Nature Medicine, Lancet, JCI, PNAS, step is cultivating in translational professionals the
Nature Rheumatology, A&R, ARD, etc) and by necessary awareness, knowledge and experience to
approximately 100 patents. contribute significantly to the advancement of the
field.
Eureka Institute for Translational Medicine
629 4th Street • Encinitas, California USA 92024 • +1.619.820.2272 • Consulenza Impresa srl • Viale Teracati, 50 • Siracusa, Italia 96100
25You can also read
